Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>ON-013100

ON-013100

Catalog No.GC33353

ON-013100, un médicament antinéoplasique, agit comme un inhibiteur mitotique qui pourrait inhiber l'expression de la cycline D1.

Products are for research use only. Not for human use. We do not sell to patients.

ON-013100 Chemical Structure

Cas No.: 865783-95-5

Taille Prix Stock Qté
10mM (in 1mL DMSO)
109,00 $US
En stock
1mg
63,00 $US
En stock
5mg
126,00 $US
En stock
10mg
195,00 $US
En stock
50mg
767,00 $US
En stock
100mg
1 290,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.

ON-013100 induces apoptosis, and has activity against most human cancer cell lines in vitro

[1]. Cho SY, et al. Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS. J Pharm Biomed Anal. 2013 Mar 5;75:138-44. [2]. Park IW, et al. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene. 2007 Aug 16;26(38):5635-42. [3]. Neel Jasani, et al. Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA.

Avis

Review for ON-013100

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ON-013100

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.